Patient Group Urges HHS Panel to Push for Oversight of Dx Firms' Marketing Practices | GenomeWeb

By Turna Ray

Citing reports that test developer Myriad Genetics discourages patients from seeking guidance from genetic counselors, a patient advocacy group urged the HHS Secretary's Advisory Committee on Genetics, Health, and Society last week to recommend that federal agencies monitor the unethical marketing practices of diagnostics companies and encourage patients to seek genetic counseling prior to getting tested.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.